Experimental cocktail aims to tackle returning brain tumors
NCT ID NCT06061809
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests a mix of immune-boosting drugs, natural killer cells, and a device that sends low-intensity electric fields to the brain for people with glioblastoma that has come back after initial treatment. The trial has two parts: first, everyone gets the drug combo; second, participants are split into two groups, one adding the electric field device. The goal is to see if the combination is safe and can control the tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nogapendekin alfa inbakicept (N-803), PD-L1 t-haNK cells, bevacizumab, and tumor treating fields (TTFields)
What this could lead to
If successful, this combination could offer a new treatment option for people with recurrent glioblastoma, potentially slowing tumor growth and extending survival.
What could go wrong
This is an early-phase trial with only 34 participants, so results may not apply to everyone. The combination therapy may cause serious side effects, and it is not yet known if it works better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chan Soon-Shiong Institute for Medicine (CSSIFM)
El Segundo, California, 90245, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Providence Medical Foundation
Fullerton, California, 92835, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37203, United States